Spyre Therapeutics (NASDAQ: SYRE) CFO receives 140,000 options award

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. reported an insider equity award to its Chief Financial Officer, Scott L. Burrows, in a Form 4 filing. On January 9, 2026, he was granted a stock option to purchase 140,000 shares of Spyre Therapeutics common stock at an exercise price of $30.61 per share. The option is a derivative security and is held directly.

The filing states that this option will vest in equal monthly installments over four years, and each vesting installment is conditioned on his continued employment with the company at the relevant vesting date. Following this grant, Burrows beneficially owns 140,000 stock options, with the option scheduled to expire on January 9, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burrows Scott L

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.61	01/09/2026		A		140,000		(1)	01/09/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Spyre Therapeutics (SYRE) report in this Form 4?

The Form 4 reports that Chief Financial Officer Scott L. Burrows received a grant of a stock option for 140,000 shares of Spyre Therapeutics common stock on January 9, 2026.

What are the key terms of Scott L. Burrows' stock option grant at Spyre Therapeutics (SYRE)?

The grant is a Stock Option (Right to Buy) for 140,000 shares of common stock at an exercise price of $30.61 per share, vesting in equal monthly installments over four years, subject to his continued employment at each vesting date.

How many Spyre Therapeutics (SYRE) derivative securities does the CFO own after this transaction?

After the reported transaction, Scott L. Burrows beneficially owns 140,000 stock options relating to Spyre Therapeutics common stock, held directly.

When do the granted Spyre Therapeutics (SYRE) stock options expire?

The stock option granted to Scott L. Burrows has an expiration date of January 9, 2036, as disclosed in the Form 4.

How does the vesting of the Spyre Therapeutics (SYRE) CFO stock options work?

The filing explains that the option for 140,000 shares will vest in equal monthly installments over four years, and each installment requires the CFO to remain employed by Spyre Therapeutics on the relevant vesting date.

Is the reported Spyre Therapeutics (SYRE) transaction a derivative or non-derivative security?

The transaction involves a derivative security, specifically a Stock Option (Right to Buy) that is exercisable for Spyre Therapeutics common stock.